key: cord-0695921-rd1tbb8u authors: Rafiullah, Mohamed title: Can a combination of AT1R antagonist and vitamin D treat the lung complication of COVID-19? date: 2020-07-15 journal: Am J Med Sci DOI: 10.1016/j.amjms.2020.07.018 sha: 3860b257a16ebd5baf1a392e26d0cea034ebbf1b doc_id: 695921 cord_uid: rd1tbb8u Severe Acute Respiratory Distress Syndrome caused by a novel human coronavirus SARS-CoV-2 named COVID-19 and declared as a pandemic. This paper reviews the possibility of repurposing angiotensin type 1 receptor (AT1R) antagonists and vitamin D to treat COVID-19. ACE2 protein found on the cell membranes is the target of SARS-CoV-2 for entering into the host cells. Viral spike protein-binding with ACE2 down-regulates it. As ACE2 is known to protect the lung from injuries, SARS-CoV-2-induced ACE2 deficiency may expose patients to lung damage. AT1R antagonists and vitamin D increase the expression of ACE2 independently. Besides, vitamin D suppresses the compensatory increase in renin levels following the inhibition of the renin-angiotensin system by AT1R antagonists. Therefore, a combination of AT1R antagonists and vitamin D may offer protection against COVID-19 induced lung injury. A novel human coronavirus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) emerged from Wuhan, China, since Dec 2019 1 Respiratory Distress Syndrome (ARDS) in susceptible patients. SARS-CoV-2 binds with angiotensin-converting enzyme 2 (ACE2) molecule for entry into the human cells 2 . The previous SARS-CoV infections were found to down-regulate the expression of ACE2 molecule 3 . Lower ACE2 levels are implicated in lung injury, whereas higher levels are protective against lung injuries 4 . Low ACE2 is also reported among aged men 5 and in chronic disease conditions 4 . The mortality rate of COVID-19 has been high among older people and those with pre-existing comorbidities such as diabetes and hypertension. Decreased levels of ACE2 in SARS-CoV-2 infections could predispose people to severe COVID-19 complications. Elevating the ACE2 levels in patients may protect them from the lung complications of COVID-19. Treatment with angiotensin type 1 receptor (AT1R) antagonists and vitamin D supplementation may present a simpler and effective way of improving ACE2 levels safely among patients. This review elaborates on the idea of using AT1R antagonists and vitamin D for treating serious lung complications of SARS-CoV-2. The entry mechanism of SARS-CoV-2 is similar to that of SARS-CoV. Viral spike S glycoprotein has to be primed by the host cell proteases before binding with the receptors. The SARS-CoV-2 uses ACE2 is used as the entry receptor 6 . Viral entry is dependent on the S protein priming by host cell surface-associated transmembrane protease serine 2. In virus infectivity studies, SARS-CoV-2 could not enter the HeLa cells that did not express ACE2 proteins. The binding affinity of SARS-CoV-2 S protein with ACE2 is 10-20 folds higher than that of SARS-CoV. The lung alveolar epithelial cells, heart, kidney, and enterocytes of the small intestine express ACE2 protein 7 . Angiotensin-converting enzyme (ACE) increases the blood pressure by converting the inactive angiotensin I to active angiotensin II which in turn binds with angiotensin type 1 receptor (AT1R) to induce vasoconstriction. ACE2 is a counter-regulatory enzyme in the renin-angiotensin system (RAS). It cleaves the angiotensin II into a potent vasodilating heptapeptide known as angiotensin 1-7 8 ACE2 has a beneficial effect on the lungs and protects it from severe injury 14 . In ACE2 deficient conditions, excessive angiotensin II causes increased vascular permeability, vasoconstriction, and inflammation in the lungs leading to ALI. ACE2 down-regulation by SARS-CoV infection was found in severe lung failure and was associated with mortality in SARS infection 9 . Similarly, in SARS-CoV-2 infection, the ACE2 deficiency after the viral spike binding and the subsequent imbalance in the RAS may mediate the ALI. A recent study on the clinical and biochemical indexes of COVID-19 patients showed angiotensin II levels were markedly higher than healthy individuals and were linearly associated with the viral load and lung injury 15 . As ACE2 protein protects the lungs, and COVID-19 patients have lower levels of ACE2, increasing the ACE2 level is likely to protect against SARS-CoV-2 induced lung injury. Therapeutic approaches to increase ACE2 levels may work as a good strategy in treating SARS-CoV-2 infections. AT1R antagonists can be used to increase ACE2 protein levels. ACE inhibitors are not preferred because they cause cough, a common adverse effect associated with their use. ACE2 being the target molecule of SARS-CoV-2 viral spike protein, increasing its level may also increase the viral load. However, the European Society of Cardiology Council on Hypertension stated that there is no evidence supporting any harmful effect of ACE inhibitors in COVID-19 infections. It even hinted about the possible beneficial effects of ACE inhibitors while referring observations from animal studies 16 . Recently there are suggestions to use AT1R antagonists as a strategy of increasing ACE2 levels for treating COVID-19 infections [17] [18] [19] . Vitamin D has a negative regulatory role on the RAS. Suppression of RAS by AT1R antagonists results in a feedback-induced compensatory increase in renin. Vitamin D blocks the rise in renin at the transcriptional level when given in combination with a RAS inhibitor such as AT1R antagonists or ACE inhibitors 20 . Renin is an enzyme involved in the production of angiotensin II. It converts angiotensinogen to angiotensin I, a precursor of angiotensin II. Inhibition of renin will decrease the levels of proinflammatory angiotensin II and alleviate lung injury. Vitamin D was effective in attenuating the lipopolysaccharide-induced ALI in rats by modulating the RAS. It inhibited renin, ACE and angiotensin II expression and induced ACE2 levels 21 . With its inhibitory effect on renin, the simultaneous administration of vitamin D may complement the effect of AT1R antagonists. Besides, vitamin D has a direct protective effect on the lungs. Its deficiency appeared to contribute to the ARDS 22 and was associated with increased admissions to the intensive care unit and mortality in patients with pneumonia. Vitamin D status was associated with 30 days mortality rate in patients with community-acquired pneumonia 23 . A retrospective study on Korean patients with ARDS showed that vitamin D deficiency was prevalent among them, and the serum levels correlated inversely with length of hospital stay and intensive care unit stay among in-hospital survivors 24 . Vitamin D inhibits pulmonary inflammatory responses and improves the host defense mechanisms against respiratory infections 25 . In a meta-analysis of individual patient data from 25 randomized controlled trials, vitamin D supplementation reduced the risk of acute respiratory tract infection among participants 26 The present review indicates that AT1R antagonists or vitamin D or a combination may be useful in treating the lung complication of COVID-19. Appropriately designed clinical studies are needed to establish the benefit of the combination of AT1R antagonists with vitamin D. However, the role of these drugs in patients who do not develop lung complications is not clear. Naming the coronavirus disease (COVID-19) and the virus that causes it. Country & Technical Guidance -Coronavirus disease (COVID-19 Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Gallagher T Replication-dependent downregulation of cellular angiotensinconverting enzyme 2 protein expression by human coronavirus NL63 Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease Age-and gender-related difference of ACE2 expression in rat lung SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor A pneumonia outbreak associated with a new coronavirus of probable bat origin ACE2 of the heart: From angiotensin I to angiotensin (1-7) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Angiotensin-converting enzyme 2 protects from severe acute lung failure Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers (CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-aceinhibitors-and-ang Response to the emerging novel coronavirus outbreak Read our latest coverage of the Coronavirus outbreak Rapid Response Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics Response to the emerging novel coronavirus outbreak Molecular mechanism of vitamin D in the cardiovascular system Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the reninangiotensin system Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS) Addition of Vitamin D Status to Prognostic Scores Improves the Prediction of Outcome in Community-Acquired Pneumonia Effect of vitamin D deficiency in korean patients with acute respiratory distress syndrome Vitamin D and respiratory health Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data The author would like to acknowledge the National Plan for Science, Technology and